Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus CAPOX in MSS Locally Advanced Colon Cancer
NCT07132008Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in colon cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07132008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132008.